Press Release Details
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
Conference Call and Webcast Today at
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 4788374.
A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 4788374.
Selected Fiscal 2018 First Quarter and Recent Events
- Filed a Clinical Trial Application for ARO-AAT, a second generation subcutaneously administered clinical candidate for the treatment of alpha-1 antitrypsin deficiency liver disease
- Filed a Clinical Trial Application for ARO-HBV, a third generation subcutaneously administered clinical candidate for the treatment of chronic hepatitis B virus infection
- Presented new clinical data at HEP DART 2017 demonstrating up to 5.0 log10 reduction in HBV s-antigen and a Sustained Host Response in 50% of hepatitis B patients following RNAi therapy, ARC-520, in the 2001 open-label extension study
- Made continued progress on a two-product cardiovascular collaboration with Amgen, in which one that was previously called ARO-LPA against the target lipoprotein(a) has been formally nominated as a potential clinical candidate and which is now referred to as AMG 890 by Amgen
- Expanded Arrowhead's cardiometabolic pipeline, which now includes ARO-APOC3, targeting apolipoprotein C-III, and ARO-ANG3, targeting angiopoietin-like protein 3 (ANGPTL3); with CTA filings planned around the end of 2018
-
Achieved continued progress with the Company's extra-hepatic platform
and pipeline, including:
- ARO-Lung1, Arrowhead's first candidate against an undisclosed gene target in the lung, which achieved nearly 90% target knockdown following inhaled administration in rodents
- ARO-HIF2, the Company's candidate targeting renal cell carcinoma, which achieved 85% target gene knockdown in a rodent tumor model
Selected Fiscal 2018 First Quarter Financial Results
|
|
||||||||
| CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited) | ||||||||
| Three Months Ended | ||||||||
|
|
||||||||
|
OPERATING SUMMARY |
2017 | 2016 | ||||||
| REVENUE | $ | 3,509,821 | $ | 4,365,496 | ||||
| OPERATING EXPENSES | ||||||||
| Research and development | 8,431,903 | 9,527,051 | ||||||
| Salaries and payroll-related costs | 3,986,367 | 4,276,105 | ||||||
| General and administrative expenses | 1,671,185 | 1,854,174 | ||||||
| Stock-based compensation | 2,092,541 | 2,424,442 | ||||||
| Depreciation and amortization | 1,141,173 | 1,185,611 | ||||||
| TOTAL OPERATING EXPENSES | 17,323,169 | 19,267,383 | ||||||
| OPERATING LOSS | (13,813,348 | ) | (14,901,887 | ) | ||||
| OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES | 614,470 | 2,815,779 | ||||||
| NET LOSS | $ | (13,198,878 | ) | $ | (12,086,108 | ) | ||
| NET LOSS PER SHARE (BASIC AND DILUTED): | $ | (0.18 | ) | $ | (0.17 | ) | ||
| WEIGHTED AVERAGE SHARES OUTSTANDING | 74,831,415 | 71,444,600 | ||||||
|
FINANCIAL POSITION SUMMARY |
|
|
||||||
|
2017 |
2017 |
|||||||
| CASH AND CASH EQUIVALENTS | $ | 11,531,345 | $ | 24,838,567 | ||||
| SHORT-TERM INVESTMENTS | 39,169,376 | 40,769,539 | ||||||
| TOTAL CASH RESOURCES (CASH AND INVESTMENTS) | 50,700,721 | 65,608,106 | ||||||
| OTHER ASSETS | 37,519,772 | 38,414,174 | ||||||
| TOTAL ASSETS | 88,220,493 | 104,022,280 | ||||||
| TOTAL LIABILITIES | 18,021,183 | 23,155,118 | ||||||
| TOTAL STOCKHOLDERS' EQUITY | 70,199,310 | 80,867,162 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 88,220,493 | $ | 104,022,280 | ||||
| SHARES OUTSTANDING | 74,917,876 | 74,785,426 | ||||||
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: http://www.businesswire.com/news/home/20180209005693/en/
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Source:
News Provided by Acquire Media